GSK1120212
Showing 1 - 25 of 77
BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma Trial in Duarte, Columbus (Dabrafenib,
Recruiting
- BRAF NP_004324.2:p.V600E
- +2 more
- Dabrafenib
- +2 more
-
Duarte, California
- +1 more
Jan 19, 2023
Metastatic Malignant Tumor in the Brain Trial in Columbus (other, procedure, drug, radiation)
Active, not recruiting
- Metastatic Malignant Neoplasm in the Brain
- Laboratory Biomarker Analysis
- +4 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Oct 15, 2022
Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer Trial in Salt Lake City
Recruiting
- Metastatic Pancreatic Carcinoma
- +6 more
-
Salt Lake City, UtahHuntsman Cancer Institute/University of Utah
Oct 31, 2022
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID
Active, not recruiting
- Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
- +2 more
- Dabrafenib
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Aug 9, 2022
Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma Trial in Houston, Salt Lake City (procedure, drug,
Recruiting
- Thyroid Gland Anaplastic Carcinoma
- Thyroid Gland Squamous Cell Carcinoma
- Conventional Surgery
- +5 more
-
Stanford, California
- +5 more
Jan 26, 2023
EGFR NP_005219.2:p.S492R, KRAS Gene Mutation, MAP2K1 Gene Mutation Trial in Houston (other, biological, drug)
Recruiting
- EGFR NP_005219.2:p.S492R
- +7 more
- Laboratory Biomarker Analysis
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Dec 5, 2022
BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Tumor Trial in Boston (Dabrafenib,
Active, not recruiting
- BRAF V600E Mutation Present
- +9 more
- Dabrafenib
- +4 more
-
Boston, Massachusetts
- +1 more
Jun 28, 2022
Leukemia, Juvenile Myelomonocytic, JMML, JCML Trial (Trametinib, Azacitidine, Fludarabine)
Not yet recruiting
- Leukemia, Juvenile Myelomonocytic
- +4 more
- Trametinib
- +3 more
- (no location specified)
May 4, 2023
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma Trial in Canada (Laboratory Biomarker Analysis, Pharmacological
Completed
- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma
- Laboratory Biomarker Analysis
- +3 more
-
Calgary, Alberta, Canada
- +4 more
Feb 10, 2022
Advanced Uveal Melanoma, Metastatic Uveal Melanoma, Unresectable Uveal Melanoma Trial (BRD4 Inhibitor PLX2853, Trametinib,
Not yet recruiting
- Advanced Uveal Melanoma
- +2 more
- BRD4 Inhibitor PLX2853
- +4 more
- (no location specified)
Jan 9, 2023
Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in Boston
Active, not recruiting
- Metastatic Malignant Solid Neoplasm
- +2 more
- Biopsy
- +6 more
-
Boston, Massachusetts
- +1 more
Nov 8, 2022
Pancreatic Ductal Adenocarcinoma Trial in Miami (Trametinib, Ruxolitinib, Retifanlimab)
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- Trametinib
- +2 more
-
Miami, FloridaUniversity of Miami
Jun 27, 2022
BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma Trial in Boston (drug, biological, other)
Terminated
- BRAF V600E Mutation Present
- +7 more
- Dabrafenib
- +4 more
-
Boston, Massachusetts
- +1 more
Mar 9, 2022
Advanced Malignant Solid Tumor, EGFR Gene Amplification, EGFR Gene Mutation Trial in Houston (Everolimus, Neratinib,
Recruiting
- Advanced Malignant Solid Neoplasm
- +9 more
- Everolimus
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Oct 25, 2022
Malignant Tumors of Digestive Organs, Colorectal Cancer, Colon Cancer Trial in Houston (Durvalumab, Trametinib)
Completed
- Malignant Neoplasms of Digestive Organs
- +2 more
-
Houston, TexasUniversity of Texas MD Anderson Cancer Center
May 23, 2022
KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma, Recurrent Non-Squamous Non-Small Cell Lung Carcinoma
Active, not recruiting
- KRAS Gene Mutation
- +3 more
- Pembrolizumab
- Trametinib
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Nov 1, 2021
Recurrent World Health Organization (WHO) Grade II Glioma Trial in United States (Everolimus, Trametinib)
Recruiting
- Recurrent World Health Organization (WHO) Grade II Glioma
-
Birmingham, Alabama
- +11 more
May 6, 2022
Advanced Malignant Solid Tumor Trial in United States (Adavosertib, Carboplatin, Everolimus)
Completed
- Advanced Malignant Solid Neoplasm
- Adavosertib
- +5 more
-
Aurora, Colorado
- +7 more
Apr 11, 2022
Thyroid Gland Anaplastic Carcinoma Trial in Saint Petersburg (Dabrafenib, Trametinib)
Recruiting
- Thyroid Gland Anaplastic Carcinoma
-
Saint Petersburg, Russian FederationSaint-Petersburg State University (SPSU) N.I.Pirogov Clinic of H
Feb 3, 2021
Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Rectal Carcinoma Trial in United States (Laboratory
Active, not recruiting
- Metastatic Colon Carcinoma
- +24 more
- Laboratory Biomarker Analysis
- +2 more
-
Corona, California
- +7 more
Oct 26, 2022
Breast Cancer Trial in Chapel Hill (GSK1120212)
Completed
- Breast Cancer
- GSK1120212
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center
Sep 1, 2020
Advanced and Selected Solid Tumors Trial in Worldwide (BKM120, GSK1120212)
Completed
- Advanced and Selected Solid Tumors
- BKM120
- GSK1120212
-
Los Angeles, California
- +6 more
Dec 6, 2020
Recurrent Rectal Cancer, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer Trial in United States (trametinib, fluorouracil,
Active, not recruiting
- Recurrent Rectal Cancer
- +6 more
- trametinib
- +2 more
-
Saint Louis, Missouri
- +3 more
Feb 15, 2022
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Tumor Trial in
Active, not recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +4 more
- Dabrafenib
- +4 more
-
Phoenix, Arizona
- +48 more
Jan 3, 2023